default author photo

Marius Trøseid

Section for Clinical Immunology and Infectious Diseases

SCHOLARLY PAPERS

4

DOWNLOADS

779

TOTAL CITATIONS

5

Scholarly Papers (4)

1.

Evaluation of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 Patients: Results from the NOR-Solidarity Randomised Trial

Number of pages: 33 Posted: 11 Feb 2021
Vestre Viken Hospital Trust, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Department of Research Support for Clinical Trials, University of Oslo - Oslo University Hospital, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, Vestre Viken Hospital Trust, Diakonhjemmet Hospital, Sørlandet Hospital, Innlandet Hospital, University Hospital North Norway, University of Stavanger - Stavanger University Hospital, University of Oslo - Institute of Clinical Medicine, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Oslo University Hospital, District General Hospital of Førde - Section for Rheumatology, Haugesund Hospital, Vestre Viken Hospital Trust, Vestre Viken Hospital Trust, Møre og Romsdal Hospital Trust, Telemark Hospital Trust, Haraldsplass Deaconess Hospital, Sørlandet Hospital, Independent, Innlandet Hospital Trust, Høgskolen i Nord-Trøndelag, University of Oslo - Institute of Clinical Medicine, University of Oslo - Department of Immunology and Transfusion Medicine, Trondheim University Hospital, Akershus University Hospital - Department of Infectious Diseases, Lovisenberg Diaconal Hospital - Department of Medicine, University of Oslo - Institute of Clinical Medicine, University of Bergen - Department of Clinical Science, Østfold Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Section for Clinical Immunology and Infectious Diseases, University of Oslo - Institute of Clinical Medicine and University of Oslo - Department of Immunology and Transfusion Medicine
Downloads 331
Citation 5

Abstract:

Loading...

2.

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Number of pages: 34 Posted: 03 Aug 2022
University of Oslo - Section for Clinical Immunology and Infectious Diseases, Universidad Autónoma de Madrid, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Institute of Clinical Medicine, University of Lille, affiliation not provided to SSRN, University of Verona, Hospital Universitario Virgen Macarena - Unidad Clínica de Enfermedades Infecciosas, affiliation not provided to SSRN, Université Libre de Bruxelles (ULB), Medical University of Innsbruck, Government of Portugal - Unidade Local de Saúde de São João, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Division of Emergencies and Critical Care, University of Claude Bernard Lyon 1, affiliation not provided to SSRN, University of Pécs, National and Kapodistrian University of Athens, University Hospital Brno, University of Basel - University Hospital Basel, Hacettepe University, Technische Universität München (TUM), Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, Vestre Viken Hospital Trust, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, University of Oslo - Institute of Clinical Medicine, University of Stavanger - Stavanger University Hospital, Hospital Universitario La Paz, Vestre Viken Hospital Trust, University Hospital North Norway, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, Akershus University Hospital - Department of Infectious Diseases, Norwegian Institute of Public Health, Sorbonne University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Department of Immunology and Transfusion Medicine, Hospices Civils de Lyon - Laboratoire de Virologie, University of Nantes - INSERM, University of Oslo - Oslo University Hospital, Norwegian Institute of Public Health, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, affiliation not provided to SSRN, University of Oslo - Department of Research Support for Clinical Trials and Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP
Downloads 176

Abstract:

Loading...

COVID-19, immunomodulator, safety, baricitinib, JAK inhibitor

3.

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 27 Posted: 03 Oct 2024
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, University of Basel, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University Hospitals of Geneva, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), The Emmes Company, Hospital Universitario de Fuenlabrada, Hospital Universitario de Fuenlabrada, Ospedali Riuniti di Ancona, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Mazandaran University of Medical Sciences, University of Cambridge, NHS Foundation Trust - Cambridge University Hospitals, Hospital Universitario La Paz, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Hospital Israelita Albert Einstein, Hospital Israelita Albert Einstein, University of Sydney - George Institute for Global Health, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Norwegian Institute of Public Health, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Université Libre de Bruxelles (ULB) - Department of Infectious Disease, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, Hôpital Bichat, APHP, Université Paris Cité, Université Paris Cité, Université Paris Cité, University of Nantes - INSERM, Sorbonne University, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Section for Clinical Immunology and Infectious Diseases and University of Basel - University Hospital Basel
Downloads 175

Abstract:

Loading...

4.

Safety of Baricitinib in Vaccinated Patients with Severe and Critical COVID-19. Sub Study of the Randomised Bari-SolidAct Trial

Number of pages: 30 Posted: 19 Jul 2024
University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Lyon Sud Hospital, University of Lille, Hospital Universitario La Paz, Hospices Civils de Lyon, University of Claude Bernard Lyon 1, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Nantes - INSERM, University of Nantes - INSERM, University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Institute of Clinical Medicine, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Amiens Picardie University Hospital - Intensive Care Unit, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, University of Bordeaux - CHU de Bordeaux, University of Bordeaux - CHU de Bordeaux, Assistance Publique-Hôpitaux de Paris - Service de Réanimation Médicale Et Infectieuse (MI2), Université Paris Cité, Louis Mourier Hospital, University of Dijon - Clinical Epidemiology/Clinical Trials Unit, University of Nantes - INSERM, Centro Hospitalar Universitário de Lisboa Central, University of Oslo, Vestre Viken Hospital Trust, Vestre Viken Hospital Trust, University of Stavanger - Stavanger University Hospital, University of Oslo - Oslo University Hospital, University Hospital North Norway, Østfold Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, University of Oslo - Oslo University Hospital, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine and University of Oslo - Section for Clinical Immunology and Infectious Diseases
Downloads 97

Abstract:

Loading...

COVID-19, vaccination, baricitinib, JAK inhibitors, immunomodulation, elderly